SCHEMBL2495979

SCHEMBL2495979

CCc1ccccc1N(C)CC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 1/20 0.41
GABRA1 P14867 2/20 0.39
GABRB2 P47870 2/20 0.39
LMNA P02545 3/20 0.35
TSHR P16473 4/20 0.34
MAPT P10636 3/20 0.34
GAA P10253 2/20 0.34
TP53 P04637 2/20 0.34
ALDH1A1 P00352 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
NPSR1 Q6W5P4 3/20 0.34
L3MBTL1 Q9Y468 3/20 0.34
AR P10275 1/20 0.34
HPGD P15428 2/20 0.34
HTT P42858 2/20 0.34
NPC1 O15118 1/20 0.34
KDM4E B2RXH2 1/20 0.34
GPR55 Q9Y2T6 1/20 0.34
MAPK1 P28482 1/20 0.33
MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31718392 0.88 SIGMAR1 (0.37) LMNATSHRMAPTGAATP53
SCHEMBL709848 0.81 MAPT (0.46) MGLLGABRA1GABRB2LMNATSHR
SCHEMBL26418632 0.81 ALDH1A1 (0.41) LMNATSHRMAPTGAATP53
SCHEMBL8099691 0.81 MGLL (0.43) MGLLGABRA1GABRB2LMNATSHR
SCHEMBL19661689 0.81 TAAR1 (0.41) MGLLGABRA1GABRB2MAPTMEN1
SCHEMBL13306234 0.79 MAPT (0.41) MGLLMAPTGAATP53ALDH1A1
Hydrochloric Acid SCHEMBL2863619 0.79 MAPT (0.45) MGLLGABRA1GABRB2LMNATSHR
SCHEMBL462452 0.79 AR (0.49) MGLLGABRA1GABRB2LMNATSHR
SCHEMBL31718393 0.79 TSHR (0.39) LMNATSHRMAPTGAAALDH1A1
SCHEMBL27456556 0.79 MAPT (0.45) MGLLGABRA1GABRB2LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023072248-A1 PYRIDYL-CONTAINING COMPOUND 正大天晴药业集团股份有限公司 2023-05-04 WO disclosed
WO-2023287783-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF ACEA Therapeutics, Inc. (US) 2023-01-19 WO disclosed
CN-107207983-B Use of a lubricating composition 国际壳牌研究有限公司 2022-11-18 CN disclosed
CN-108700835-B Resist pattern forming method and resist 日本瑞翁株式会社 2022-05-27 CN disclosed
EP-3885344-A2 PYRIMIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF InventisBio Co., Ltd. (CN) 2021-09-29 EP disclosed
EP-3526198-B1 3-SULFONYL-5-AMINOPYRIDINE-2,4-DIOL APJ AGONISTS BRISTOL MYERS SQUIBB CO (US) 2020-08-12 EP disclosed
CN-104238270-B Composition, method for forming pattern, crystal grain and method for manufacturing display device 奇美实业股份有限公司 2018-11-09 CN disclosed
CN-108700812-A RADIATION-SENSITIVE RESIN COMPOSITION AND RESIST 日本瑞翁株式会社 2018-10-23 CN disclosed
CN-108700835-A Resist pattern forming method and resist 日本瑞翁株式会社 2018-10-23 CN disclosed
CN-104345557-B Negative photosensitive resin composition, pattern, crystal grain and device manufacturing method 奇美实业股份有限公司 2018-06-22 CN disclosed
CN-104345557-A Negative photosensitive resin composition, pattern, crystal grain and device manufacturing method CHI MEI CORP 2015-02-11 CN disclosed
CN-104238270-A Composition, method for forming pattern, crystal grain and method for manufacturing display device CHI MEI CORP 2014-12-24 CN disclosed
US-20140363915-A1 NEGATIVE PHOTOSENSITIVE RESIN COMPOSITION AND APPLICATION THEREOF CHI MEI CORPORATION (TW) 2014-12-11 US disclosed
EP-2426128-A1 Carbostyril compound Otsuka Pharmaceutical Co., Limited (JP) 2012-03-07 EP disclosed
US-8030529-B2 Process for the preparation of intermediates SYNGENTA CROP PROTECTION, INC. (US) 2011-10-04 US disclosed
CN-102036990-A Novel tyrosine kinase inhibitors CHEMBRIDGE CORP 2011-04-27 CN disclosed
US-20090023964-A1 PROCESS FOR THE PREPARATION OF INTERMEDIATES SYNGENTA CROP PROTECTION, INC. (US) 2009-01-22 US disclosed
US-7388021-B2 Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions BRISTOL MYERS SQUIBB COMPANY (US) 2008-06-17 US disclosed
EP-1848678-A1 PROCESS FOR THE PREPARATION OF INTERMEDIATES Syngeta Participations AG (CH) 2007-10-31 EP disclosed
WO-2006084663-A1 PROCESS FOR THE PREPARATION OF INTERMEDIATES SYNGENTA PARTICIPATIONS AG (CH) 2006-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023964-A1 PROCESS FOR THE PREPARATION OF INTERMEDIATES HPD, CYP4X1, AZI2 MGLL 3313/4885GABRA1 3295/4885GABRB2 3277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.